keyword
https://read.qxmd.com/read/38527473/single-dose-of-dengvaxia-vaccine-is-it-a-cause-for-alarm
#1
JOURNAL ARTICLE
Corazon C Buerano, Kouchi Morita
No abstract text is available yet for this article.
March 22, 2024: Lancet Infectious Diseases
https://read.qxmd.com/read/38391779/dengue-fever-epidemics-and-the-prospect-of-vaccines-a-systematic-review-and-meta-analysis-using-clinical-trials-in-children
#2
REVIEW
Ebele C Okoye, Amal K Mitra, Terica Lomax, Cedric Nunaley
About half of the world's population is at risk of dengue infection. Epidemics of dengue fever have caused an increased risk of morbidity and mortality in recent years, which led to the exploration of vaccines as a preventive measure. This systematic review and meta-analysis aimed to evaluate the efficacy, immune response, and safety of dengue vaccines in children by analyzing clinical trials. The review followed standard procedures for data extraction using PRISMA guidelines and searching multiple databases, including PubMed, CINAHL, Medline, Health Source, Science Direct, and Academic Search Premiere...
February 6, 2024: Diseases (Basel)
https://read.qxmd.com/read/38350770/implications-of-information-heard-about-dengvaxia-on-filipinos-perception-on-vaccination
#3
JOURNAL ARTICLE
Maria Angela A Mabale, Lourdes Marie S Tejero, Lucille A Montes, Ma Theresa M Collante, Ma Sandra B Tempongko, Ma Carmen C Tolabing
Issues that arose from the Dengvaxia vaccination program in the Philippines in 2017 were followed by a remarkable decline in immunization coverage in the country. This study intended to describe the Filipinos' perceptions about vaccination after hearing about the Dengvaxia vaccine and the vaccination program and determine its potential relationship with selected demographic factors and other variables such as: health literacy, sources of information on Dengvaxia, information heard about the vaccine, healthcare visits, and perceived health status...
February 12, 2024: Vaccine
https://read.qxmd.com/read/38331225/potential-of-several-triazene-derivatives-against-dengue-viruses
#4
JOURNAL ARTICLE
Seynabou Sokhna, Natacha Mérindol, Marc Presset, Insa Seck, Marie-Pierre Girard, Seydou Ka, Samba Fama Ndoye, Aïcha Lalla Ba, Issa Samb, Lionel Berthoux, Erwan Le Gall, Isabel Desgagné-Penix, Matar Seck
Dengue fever is an infectious disease caused by the dengue virus (DENV), an RNA Flavivirus transmitted by the mosquitoes Aedes aegypti and Aedes albopictus widespread in tropical, subtropical and also temperate regions. Symptoms range from a simple cold to a severe, life-threatening haemorrhagic fever. According to the WHO, it affects around 390 million people per year. No antiviral treatment for DENV is available, and the Dengvaxia vaccine is only intended for people over 9 years of age who have contracted dengue one time in the past, and shows serotype-specific effectiveness...
February 6, 2024: Bioorganic & Medicinal Chemistry Letters
https://read.qxmd.com/read/38140260/a-novel-comprehensive-a129-mouse-model-for-investigating-dengue-vaccines-and-evaluating-pathogenesis
#5
JOURNAL ARTICLE
Mya Myat Ngwe Tun, Khine Mya Nwe, Jean Claude Balingit, Yuki Takamatsu, Shingo Inoue, Basu Dev Pandey, Takeshi Urano, Michinori Kohara, Kyoko Tsukiyama-Kohara, Kouichi Morita
In search of a mouse model for use in evaluating dengue vaccines, we assessed A129 mice that lacked IFN-α/β receptors, rendering them susceptible to dengue virus (DENV) infection. To our knowledge, no reports have evaluated dengue vaccine efficiency using A129 mice. A129 mice were given a single intraperitoneal (IP) or subcutaneous (SC) injection of the vaccine, Dengvaxia. After 14 days of immunization via the IP or SC injection of Dengvaxia, the A129 mice exhibited notably elevated levels of anti-DENV immunoglobulin G and neutralizing antibodies (NAb) targeting all four DENV serotypes, with DENV-4 displaying the highest NAb levels...
December 15, 2023: Vaccines
https://read.qxmd.com/read/38021722/updates-in-the-management-of-dengue-shock-syndrome-a-comprehensive-review
#6
REVIEW
Rakshit K Singh, Aakriti Tiwari, Prasiddhi D Satone, Tannu Priya, Revat J Meshram
Dengue is a very serious public health problem that can manifest a wide range of symptoms from asymptomatic to fatal conditions, such as dengue shock syndrome (DSS). It is a life-threatening mosquito-borne viral infection widely spread in tropical areas. Dengue virus transmission occurs from an infected Aedes mosquito to humans. Various factors are responsible for the occurrence of the disease, such as viral load, age of the host, immune status of the host, and genetic variability. Dengue infection occurs in three phases: febrile, critical, and recovery...
October 2023: Curēus
https://read.qxmd.com/read/37962048/exploring-the-targets-of-dengue-virus-and-designs-of-potential-inhibitors
#7
JOURNAL ARTICLE
Sayan Nath, Piyali Malakar, Baisakhi Biswas, Suryatapa Das, Nahid Shabnam, Sisir Nandi, Asmita Samadder
BACKGROUND: Dengue, a mosquito-borne viral disease spread by the dengue virus (DENV), has become one of the most alarming health issues in the global scenario in recent days. The risk of infection by DENV is mostly high in tropical and subtropical areas of the world. The mortality rate of patients affected with DENV is ever-increasing, mainly due to a lack of anti-dengue viral-specific synthetic drug components. INTRODUCTION: Repurposing synthetic drugs has been an effective tool in combating several pathogens, including DENV...
November 13, 2023: Combinatorial Chemistry & High Throughput Screening
https://read.qxmd.com/read/37962036/dengue-vaccination-towards-a-new-dawn-of-curbing-dengue-infection
#8
REVIEW
Sidhant Jain, Neha Vimal, Nilza Angmo, Madhumita Sengupta, Suraj Thangaraj
Dengue is an infectious disease caused by dengue virus (DENV) and is a serious global burden. Antibody-dependent enhancement and the ability of DENV to infect immune cells, along with other factors, lead to fatal Dengue Haemorrhagic Fever and Dengue Shock Syndrome. This necessitates the development of a robust and efficient vaccine but vaccine development faces a number of hurdles. In this review, we look at the epidemiology, genome structure and cellular targets of DENV and elaborate upon the immune responses generated by human immune system against DENV infection...
November 14, 2023: Immunological Investigations
https://read.qxmd.com/read/37933502/whole-genome-sequencing-of-outbreak-strains-from-2017-18-reveals-an-endemic-clade-of-dengue-1-virus-in-cameroon
#9
JOURNAL ARTICLE
Bright Agbodzi, Francine Berlange Sado Yousseu, Fredy Brice Nemg Simo, Selassie Kumordjie, Clara Yeboah, Mba-Tihssommah Mosore, Ronald E Bentil, Heather G Coatsworth, Naiki Attram, Shirley Nimo-Paintsil, Anne T Fox, Joseph H K Bonney, William Ampofo, Rhoel R Dinglasan, Terrel Sanders, Michael R Wiley, Maurice Demanou, Andrew G Letizia
Dengue fever is expanding as a global public health threat including countries within Africa. For the past few decades, Cameroon has experienced sporadic cases of arboviral infections including dengue fever. Here, we conducted genomic analyses to investigate the origin and phylogenetic profile of Cameroon DENV-1 outbreak strains and predict the impact of emerging therapeutics on these strains. Bayesian and maximum-likelihood phylogenetic inference approaches were employed in virus evolutionary analyses. An in-silico analysis was performed to assess the divergence in immunotherapeutic and vaccine targets in the new genomes...
November 7, 2023: Emerging Microbes & Infections
https://read.qxmd.com/read/37859315/computational-advancement-towards-the-identification-of-natural-inhibitors-for-dengue-virus-a-brief-review
#10
JOURNAL ARTICLE
Sheikh Arslan Sehgal, Iashia Tur Razia, Ayesha Kanwal, Muhammad Ahsan, Rana Adnan Tahir, Muhammad Sajid, Muhammad Saleem Khan, Naila Mukhtar, Gulnaz Parveen, Muhammad Sajid
Viral infectious illnesses represent a severe hazard to human health due to their widespread incidence worldwide. Among these ailments, the dengue virus (DENV) infection stands out. World Health Organization (WHO) estimates that DENV infection affects ~400 million people each year, with potentially fatal symptoms showing up in 1% of the cases. In several instances, academic and pharmaceutical researchers have conducted several pilot and clinical studies on a variety of topics, including viral epidemiology, structure and function analyses, infection source and route, therapeutic targets, vaccinations, and therapeutic drugs...
October 6, 2023: Combinatorial Chemistry & High Throughput Screening
https://read.qxmd.com/read/37767858/philippine-immunization-coverage-and-dengvaxia-an-infodemiological-study
#11
JOURNAL ARTICLE
Roland Dominic G Jamora, Marie Abigail R Lim, Adrian I Espiritu
BACKGROUND: A dengue vaccine, dengvaxia, was licensed for the first time in 2015. It was approved for use in 11 countries where dengue infection is endemic, including the Philippines. In November 2017, controversy arose in the Philippines regarding the dengvaxia vaccine. We hypothesized that the dengvaxia controversy might be correlated with immunization coverage in the Philippines. METHODS: We performed an analytical and infodemiological study on web-based interest in dengvaxia, both globally and in 18 dengue endemic countries, from 2015 to 2020 using Google Trends™...
2023: Pediatrics International: Official Journal of the Japan Pediatric Society
https://read.qxmd.com/read/37723635/development-in-the-inhibition-of-dengue-proteases-as-drug-targets
#12
JOURNAL ARTICLE
Muhammad Akram, Shehryar Hameed, Abbas Hassan, Khalid Khan
BACKGROUND: Viral infections continue to increase morbidity and mortality severely. The flavivirus genus has fifty different species, including the dengue, Zika, and West Nile viruses that can infect 40% of individuals globally, who reside in at least a hundred different countries. Dengue, one of the oldest and most dangerous human infections, was initially documented by the Chinese Medical Encyclopedia in the Jin period. It was referred to as "water poison," connected to flying insects, i...
September 18, 2023: Current Medicinal Chemistry
https://read.qxmd.com/read/37631896/tracing-down-the-updates-on-dengue-virus-molecular-biology-antivirals-and-vaccine-strategies
#13
REVIEW
Shiza Malik, Omar Ahsan, Hassan Mumtaz, Muhammad Tahir Khan, Ranjit Sah, Yasir Waheed
BACKGROUND: Nearly half of the world is at risk of developing dengue infection. Dengue virus is the causative agent behind this public healthcare concern. Millions of dengue cases are reported every year, leading to thousands of deaths. The scientific community is working to develop effective therapeutic strategies in the form of vaccines and antiviral drugs against dengue. METHODS: In this review, a methodological approach has been used to gather data from the past five years to include the latest developments against the dengue virus...
August 5, 2023: Vaccines
https://read.qxmd.com/read/37559696/neurological-manifestations-of-perinatal-dengue
#14
JOURNAL ARTICLE
Srijan Singh, Jubara Alallah, Astha Amrit, Akhil Maheshwari, Suresh Boppana
Dengue viruses (DENVs) are single-stranded RNA viruses belonging to the family Flaviviridae. There are four distinct antigenically related serotypes, DENVs types 1, 2, 3, and 4. These are all mosquito-borne human pathogens. Congenital dengue disease occurs when there is mother-to-fetus transmission of the virus and should be suspected in endemic regions in neonates presenting with fever, maculopapular rash, and thrombocytopenia. Although most of the infected infants remain asymptomatic, some can develop clinical manifestations such as sepsis-like illness, gastric bleeding, circulatory failure, and death...
2023: Newborn (Clarksville)
https://read.qxmd.com/read/37554332/identification-of-prior-dengue-na%C3%A3-ve-dengvaxia-recipients-with-an-increased-risk-for-symptomatic-dengue-during-fever-surveillance-in-the-philippines
#15
JOURNAL ARTICLE
Yu-Ching Dai, Ava Kristy Sy, Mario Jiz, Jih-Jin Tsai, Joan Bato, Mary Ann Quinoñes, Mary Anne Joy Reyes, Wei-Kung Wang
INTRODUCTION: Dengue virus (DENV) is the leading cause of mosquito-borne viral diseases in humans. Dengvaxia, the first licensed dengue vaccine, is recommended for DENV-seropositive individuals aged 9-45 years. In the Philippines, Dengvaxia was administered to more than 830,000 children without prior serological testing in 2016-2017. Subsequently, it was revealed that DENV-seronegative children who received Dengvaxia developed severe disease following breakthrough DENV infection. As a result, thousands of children participating in the mass vaccination campaign were at higher risk of severe dengue disease...
2023: Frontiers in Immunology
https://read.qxmd.com/read/37340460/-i-was-terrified-for-my-child-understanding-the-link-between-the-dengvaxia%C3%A2-controversy-and-the-measles-vaccine-hesitancy-in-pasay-city-philippines
#16
JOURNAL ARTICLE
Alejandro Perez Miras, Zypher Jude G Regencia, Emmanuel S Baja
BACKGROUND: The Dengvaxia® (dengue vaccine) controversy has been identified as one of the main reasons for the measles vaccine hesitancy in the Philippines. Our study aimed to identify various issues related to the Dengvaxia® controversy and to link these issues with the social perspective of measles vaccine refusal. METHODS: Semi-structured interviews and a focus group discussion using ethnography research were conducted with 41 parents and healthcare workers in Pasay City...
June 20, 2023: Journal of Public Health
https://read.qxmd.com/read/37213267/identifying-and-managing-vector-borne-diseases-in-migrants-and-recent-travelers-in-the-emergency-department
#17
REVIEW
Pauline Wiltz
PURPOSE OF REVIEW: Recognition and treatment of neglected tropical and vector-borne diseases is paramount as travel and immigration resume after a brief lull during the COVID-19 pandemic. These patients often present initially to the emergency department, and increasing physician knowledge of symptoms and treatment can reduce morbidity and mortality. This paper aims to summarize typical presentations of common tropical diseases, both neglected and vector borne, and provide the emergency physician with a diagnostic pathway based on current recommendations...
2023: Current Emergency and Hospital Medicine Reports
https://read.qxmd.com/read/37192141/epidemiologic-trends-of-dengue-in-u-s-territories-2010-2020
#18
JOURNAL ARTICLE
Kyle R Ryff, Aidsa Rivera, Dania M Rodriguez, Gilberto A Santiago, Freddy A Medina, Esther M Ellis, Jomil Torres, Ann Pobutsky, Jorge Munoz-Jordan, Gabriela Paz-Bailey, Laura E Adams
PROBLEM/CONDITION: Dengue is one of the most common vectorborne flaviviral infections globally, with frequent outbreaks in tropical regions. In 2019 and 2020, the Pan American Health Organization reported approximately 5.5 million dengue cases from the Americas, the highest number on record. In the United States, local dengue virus (DENV) transmission has been reported from all U.S. territories, which are characterized by tropical climates that are highly suitable for Aedes species of mosquitoes, the vector that transmits dengue...
May 19, 2023: MMWR Surveillance Summaries
https://read.qxmd.com/read/37158835/comparing-the-performance-of-dengue-virus-igg-and-igg-capture-enzyme-linked-immunosorbent-assays-in-seroprevalence-study
#19
JOURNAL ARTICLE
Jih-Jin Tsai, Ching-Yi Tsai, Ping-Chang Lin, Chun-Hong Chen, Wen-Yang Tsai, Yu-Ching Dai, Yen-Chia Lin, Celia Pedroso, Carlos Brites, Wei-Kung Wang
BACKGROUND: Dengue virus (DENV) is the leading cause of arboviral diseases in humans worldwide. Currently Dengvaxia, the first dengue vaccine licensed in 20 countries, was recommended for DENV seropositive individuals aged 9-45 years. Studying dengue seroprevalence can improve our understanding of the epidemiology and transmission dynamics of DENV, and facilitate future intervention strategies and assessment of vaccine efficacy. Several DENV envelope protein-based serological tests including IgG and IgG-capture enzyme-linked immunosorbent assays (ELISAs) have been employed in seroprevalence studies...
May 8, 2023: BMC Infectious Diseases
https://read.qxmd.com/read/37114191/a-dengue-vaccine-whirlwind-update
#20
REVIEW
Ruwandi Kariyawasam, Mark Lachman, Saniya Mansuri, Sumontra Chakrabarti, Andrea K Boggild
Dengue virus (DENV) is a mosquito-borne single-stranded RNA virus of the Flaviviridae family with four serotypes (DENV1, DENV2, DENV3, and DENV4) circulating many tropical and subtropical regions of the world. Endemic in more than 100 countries, DENV results in over 400 million cases annually, a subset presenting with severe or life-threatening illnesses such as dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS). While no specific treatments outside of supportive management exist, vaccines are an area of major research with two vaccines, Dengvaxia® (CYD-TDV) and Denvax® (TAK003), recently licensed for clinical use...
2023: Therapeutic Advances in Infectious Disease
keyword
keyword
168229
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.